Extended breakout or will it continue to run.
Updated
News on cancer. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-presents-new-preclinical-data-supporting
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
Trade active
>180 up since Dec. outpacing edit and crispr. still looks technically extended
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.